Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 59 for “"Dose-limiting toxicity"”.

  1. Safety profile of CAP7.1 obtained during Phase I Trial in adult patients with refractory malignancies

    Purpose: A non-randomized dose escalating phase I trial with CAP7.1, a prodrug of etoposide, was performed, to determine the safety profile, the dose limiting toxicities, and the recommended phase II dose. Furthermore, the pharmacokinetic profile was evaluated. Results: 19 patients (4 female, 19 …

    fu-berlin Repository record for Safety profile of CAP7.1 obtained during Phase I Trial in adult patients with refractory malignancies (opens in a new tab)

  2. Synthesis of novel 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as selective and potent anti-tumor agents

    … compounds are widely used, all of them show dose limiting toxicity due to their non-specific transport into normal cells as well as malignant cells. Currently, clinically used classical antifolates suffer from this disadvantage because there is no way to selectively transport them into …

    duquesne Repository record for Synthesis of novel 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as selective and potent anti-tumor agents (opens in a new tab)

  3. A Bayesian Approach to Dose-finding Studies for Cancer Therapies: Producing Personalised Procedures While Incorporating Information from Later Cycles of Therapy.

    Bayesian model based approaches for Phase I dose-finding studies are popular procedures to implement due to the efficiency of updating information sequentially after accruing information. Traditionally dose-finding studies for cancer treatments focus on the occurrence of a patient's first dose …

    lancaster Download PDF for A Bayesian Approach to Dose-finding Studies for Cancer Therapies: Producing Personalised Procedures While Incorporating Information from Later Cycles of Therapy. (opens in a new tab)

  4. A Nature Inspired Approach for Enhancing the Efficacy of Anticancer Agents

    … solid tumors where the size of antibodies is a limiting factor for effective treatment. Unfortunately, the poor pharmacokinetic profiles of many of these conjugates present a challenge, which limits their tremendous therapeutic potential. Dose-limiting toxicity is also observed due to the need …

    u-pacific Repository record for A Nature Inspired Approach for Enhancing the Efficacy of Anticancer Agents (opens in a new tab)

  5. Pharmacokinetic and pharmacodynamic mechanisms for reduced toxicity of CPT-11 by thalidomide and St John's wort

    Gastrointestinal toxicity and myelosuppression hinder the clinical use of CPT-11-based dose-intensified regimens. Clinical studies indicated that combination with thalidomide or St. Johna??s wort (SJW) alleviated CPT-11 induced toxicity. However, the underlying mechanisms involved are not fully …

    nus Repository record for Pharmacokinetic and pharmacodynamic mechanisms for reduced toxicity of CPT-11 by thalidomide and St John's wort (opens in a new tab) Download file for Pharmacokinetic and pharmacodynamic mechanisms for reduced toxicity of CPT-11 by thalidomide and St John's wort (opens in a new tab)

  6. Modified 3+3 Design for MTD Re-estimation

    … clinical trial design is one of the most popular dose-finding designs used in phase I oncology trials to identify the maximum tolerated dose (MTD) for new treatment regimens. While this design is widely used due to its simplicity , it has some notable limitations, including a maximum of six …

    iupui Repository record for Modified 3+3 Design for MTD Re-estimation (opens in a new tab)

  7. Multivalent and bispecific immunostimulatory antibodies for cancer immunotherapy

    … success, primarily due to lack of efficacy and dose-limiting toxicity. Antibody engineering can be utilised to overcome the issues with ISAs. Tetravalent anti-CD27 antibodies were developed by attaching an additional F(ab) fragments to the N-terminus of the of each IgG VH domain. This enhanced …

    soton Download PDF for Multivalent and bispecific immunostimulatory antibodies for cancer immunotherapy (opens in a new tab)

  8. Target Based Design And Synthesis of Heterocycles in the Potential Treatment of Cancer and Opportunistic Infection

    <p>Dose limiting toxicity and development of multidrug resistance by the tumors are the major limitations of current cancer chemotherapy. Microtubule targeting agents (MTAs) are a structurally diverse set of compounds that disrupt microtubule dynamics and exert their anticancer effect. Among the …

    duquesne Repository record for Target Based Design And Synthesis of Heterocycles in the Potential Treatment of Cancer and Opportunistic Infection (opens in a new tab)

  9. Dual-Criterion Dose Finding Designs for Phase I Clinical Trials

    … tolerability of novel therapeutics. Conventional dose escalation methods identify the maximum tolerated dose (MTD) based on dose-limiting toxicity (DLT). However, as cancer therapies have evolved from chemotherapy to targeted therapies, these traditional methods have become problematic. Many …

    uthsc Repository record for Dual-Criterion Dose Finding Designs for Phase I Clinical Trials (opens in a new tab)

  10. Discovery of Pyrimidine-based Heterocycles as Single Agents With Combination Chemotherapy Potential And As Inhibitors Of Purine Nucleotide Biosynthesis For The Treatment of Cancer

    … both antiangiogenic activities as well as cytotoxicity would afford agents that circumvent pharmacokinetic problems of multiple agents, avoid drug-drug interactions, could be used at lower doses to alleviate toxicity, be devoid of overlapping toxicities, and delay or prevent tumor cell …

    duquesne Repository record for Discovery of Pyrimidine-based Heterocycles as Single Agents With Combination Chemotherapy Potential And As Inhibitors Of Purine Nucleotide Biosynthesis For The Treatment of Cancer (opens in a new tab)

  11. GENETIC ENGINEERING STRATEGIES FOR EXPANDING THE THERAPEUTIC INDEX OF CHIMERIC ANTIGEN RECEPTOR CELLULAR IMMUNOTHERAPIES

    … been limited due to low therapeutic efficacy or dose-limiting toxicity. A key challenge has been to develop therapies that can trigger potent, yet manageable, immune responses capable of eliminating highly heterogeneous and immunosuppressive tumor cell populations. Here, we harness multiple …

    penn Repository record for GENETIC ENGINEERING STRATEGIES FOR EXPANDING THE THERAPEUTIC INDEX OF CHIMERIC ANTIGEN RECEPTOR CELLULAR IMMUNOTHERAPIES (opens in a new tab) Embargoed until 2028-01-22

  12. Dendrimer Nanoconjugates And Their Oral Inhalation Formulations For Lung Cancer Therapy

    … the lungs. The issue is further complicated by dose-limiting toxicity of DOX. Another major challenge in the use of DOX is its cardiac toxicity. Free DOX in bloodstream can accumulate in cardiac tissues, thus leading to fatal heart damages. On the other hand, the lungs are considered as a portal …

    wayne-thes Repository record for Dendrimer Nanoconjugates And Their Oral Inhalation Formulations For Lung Cancer Therapy (opens in a new tab)

  13. Chemoptherapy Dose Reductions in Palliative Lung Cancer. Evaluating Chemotherapy Dose Reductions following Neutropenia in Palliative Lung Cancer to prevent further Adverse Events

    … Neutropenia is a life-threatening and dose-limiting toxicity of palliative lung cancer chemotherapy. Whilst some neutropenias are inevitable, evidence suggests that patients with a previous neutropenic event are 50% more likely to have a further neutropenic event. The aim of this …

    bradford Repository record for Chemoptherapy Dose Reductions in Palliative Lung Cancer. Evaluating Chemotherapy Dose Reductions following Neutropenia in Palliative Lung Cancer to prevent further Adverse Events (opens in a new tab)

  14. The Eastern North American Woodchuck (Marmota monax) as a Biologically Relevant Model for Investigating Radiotheranostics of Human Hepatocellular Carcinoma

    … no clinically significant hematologic or renal toxicity during the 6-week follow-up. SSTR2 and SSTR5 were detected in both tumor and liver, and cytoplasmic IHC staining was present in all tumors, although high [68Ga] DOTATOC tumor uptake was found in only one animal. Histopathology revealed …

    sask Repository record for The Eastern North American Woodchuck (Marmota monax) as a Biologically Relevant Model for Investigating Radiotheranostics of Human Hepatocellular Carcinoma (opens in a new tab) Embargoed until 2028-01-05

  15. Development of Gold Nanoparticle-based Nanoformulations for Cancer Radiotherapy

    … clinical challenges in radiotherapy (RT) is dose-limiting toxicity to surrounding normal tissues. Gold nanoparticles (AuNPs) have emerged as a promising approach to overcoming this challenge by combining the radiation dose enhancement effects of Au with the unique features of nanoparticles …

    toronto-retro Repository record for Development of Gold Nanoparticle-based Nanoformulations for Cancer Radiotherapy (opens in a new tab)

  16. Home Testing of Blood Counts in Patients with Cancer

    Background: Neutropenia is a dose-limiting toxicity of chemotherapy administered to patients with cancer. Neutrophil counts are usually measured using venous samples on centralised analysers. The aim of this work was to explore the feasibility and potential of home neutrophil count monitoring …

    whiterose Download PDF for Home Testing of Blood Counts in Patients with Cancer (opens in a new tab)

  17. The design and synthesis of small molecule bromodomain inhibitors

    … trials for oncology indications. However, dose-limiting toxicities have been observed in patients which could limit their use. As the BET family consists of 4 bromodomain containing proteins (BRD2, 3, 4, and T), each of which contain 2 bromodomains (a BD1 and a BD2 domain), there is the …

    strathclyde Repository record for The design and synthesis of small molecule bromodomain inhibitors (opens in a new tab)

  18. Stability Studies of Rooperol and Analogues by In Vitro Metabolism With HPLC/MS Detection

    … patients suggested promising activity with no dose-limiting toxicity. However, rooperol is rapidly converted to biologically inactive sulfate and glucuronide metabolites. Thus, a relatively small amount of the drug reaches the tumor site. Bioisosteric analogues of rooperol have been synthesized …

    texas-state Repository record for Stability Studies of Rooperol and Analogues by In Vitro Metabolism With HPLC/MS Detection (opens in a new tab)

  19. CI-921 : a clinical, pharmacokinetic and metabolic study of a potential new cytotoxic agent

    … treatment were entered into a phase I trial. The dose of CI-921 was escalated from 39mg/m2 to 810mg/m2 (total dose divided over 3 days) and repeated 3 weekly. Neutropenia was the major dose limiting toxicity and defined a maximum tolerated dose of 810 mg/m2. Pharmacokinetic studies revealed a …

    auckland-ms Repository record for CI-921 : a clinical, pharmacokinetic and metabolic study of a potential new cytotoxic agent (opens in a new tab)

Page 1 of 3